Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program - Wikidata - awgldk - TriplyDB

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

http://www.wikidata.org/entity/Q35005309

about

Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma mTOR kinase inhibitors as potential cancer therapeutic drugs Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene.New therapeutic targets in soft tissue sarcoma.Tailoring mTOR-based therapy: molecular evidence and clinical challenges.Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.Establishment of genetically diverse patient-derived xenografts of colorectal cancer.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.Hypoxia induces a phase transition within a kinase signaling network in cancer cells A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks The mTOR pathway negatively controls ATM by up-regulating miRNAs.Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.P53 suppresses ribonucleotide reductase via inhibiting mTORC1.Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.

P2860

Q26750631-301BE8E3-E58C-42B4-A297-59BC17425391 Q27027963-DC291EDD-7600-42B7-9D1C-72349BD2F16B Q33442162-6E8D6513-ED1E-4F8D-BC20-8289CCAF3872 Q33685874-AB28EDCF-0EE5-4F00-8FA2-040C66AB6EDA Q33916861-4556CF73-C006-48FA-9D18-10160764C043 Q34267924-BF13AEFB-C904-454B-AE2A-63B47C6A0419 Q34294170-9573C406-7AD6-4CFB-8A5F-09B5D69147A7 Q34592429-34BB38DD-FBE7-4974-A84F-5BA6D6F13277 Q34601734-414F180A-6510-4BA5-B758-C89D5F7A996F Q34704942-83AF4883-E2E8-4619-BDB7-5D49BD12F0B1 Q35767389-46BF52C2-4189-4866-8F65-2A6773E4CE00 Q36386881-97160A83-FA01-467E-8061-53818977A8C4 Q36489494-274F6951-4C33-442F-9D5E-CF03A652E4CF Q36762646-0AF7B853-2DDC-426E-A24F-D25FD5E0835D Q36888962-6D96ADDB-3656-4A36-A8C7-CD4A0FAE21FE Q36906610-8ADBEE10-84D4-4D54-8FC3-6FC4EEDB4D64 Q37031690-CEDD1410-EC98-44B1-8EA7-0EE2EAA6E219 Q38105879-DFD8C399-2EAC-4CED-8452-FC39A1F9575D Q38784684-C01EF1C4-F0A4-4DAB-B9F0-7D37171E00CC Q39077562-6192E532-E025-4129-BA07-CF9F383CA9D6 Q39215732-C25CAE75-EF4B-4640-8E9F-3066A3D032BA

P2860

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

http://www.wikidata.org/entity/Q35005309

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Initial testing (stage 1) of t ...... ic preclinical testing program

@ast

Initial testing (stage 1) of t ...... ic preclinical testing program

@en

type

label

Initial testing (stage 1) of t ...... ic preclinical testing program

@ast

Initial testing (stage 1) of t ...... ic preclinical testing program

@en

prefLabel

Initial testing (stage 1) of t ...... ic preclinical testing program

@ast

Initial testing (stage 1) of t ...... ic preclinical testing program

@en

P1433

Q35005309-0EA7A4D6-499F-455A-84A8-77D2B48911F6

P1476

Q35005309-B826389B-4B8D-4143-BEFB-B0CDA6DD12BA

P2093

Q35005309-06BB05D9-3CF3-45C1-9F84-2EAA8DDA4DEC

Q35005309-19B89B3E-3B4F-45AE-B5A6-C06F8FF2A83B

Q35005309-291376F5-BA67-4CA4-81EF-92B35B4D092D

Q35005309-595FC1FD-AEDE-4F44-82B4-0BBEF17B5FAA

Q35005309-BE36AD66-DD8D-4ED4-8D35-CA8F7A637C96

Q35005309-D38A4DDC-B36E-4CC8-A387-43D044C98978

Q35005309-DCD38B61-4ECE-4E59-A639-A8B44F955961

Q35005309-E46ECCD5-73C5-4258-843A-705C52A1BCEF

P2860

Q35005309-00F1BE89-5A2D-405D-8FE5-D7A1D5D154DA

Q35005309-0A49F2F4-FE21-4B73-B1C4-45006CDB03EA

Q35005309-0CE6A4F8-01CB-4348-A79C-E36AB90AFD00

Q35005309-13DCC0C4-6260-4629-969F-809676AE67B4

Q35005309-140856A6-CA4B-4940-A288-E6A649022491

Q35005309-22B566D6-70ED-4085-BEBE-6E7D99A9293C

Q35005309-2A0A718F-AB65-4F2C-8106-A3B75CF3AFB5

Q35005309-2BC4EE28-B155-4304-837D-3452FE58B25B

Q35005309-4A9E58BF-072D-49B7-9527-4482C6570098

Q35005309-4AFC945A-4B52-4279-A8F0-124B491C2E27

P304

Q35005309-58FCE988-ECCF-4313-8004-2DED8FB0C0F3

P31

Q35005309-309A3AEB-9301-4E67-A61B-151B55F2F5E1

P356

Q35005309-072713D3-151A-4047-8FE8-033C1E059FBC

P433

Q35005309-AF4254F9-3124-4ABD-B53D-3E2748FAE39A

P478

Q35005309-E5554615-2F1E-4B58-8EDA-3CDC9871EB2B

P50

Q35005309-005EC276-BBA7-423B-B090-AECE21DFA91E

Q35005309-4989F990-811D-487C-A387-C3A40ED38CDC

Q35005309-7082ED86-2613-415E-BA2F-234FF388F71B

Q35005309-C12CD5DF-F7F8-4DB0-8D9D-C581D68940EC

Q35005309-E8659C98-95A8-4517-92ED-FFF178214ED4

P577

Q35005309-0ECB5780-98EC-40AF-9D59-D3E07BD6C4DC

P698

Q35005309-2429A877-01EF-4BEC-9F85-4AF8209FC709

P932

Q35005309-4E465B82-43B3-4B29-BE6F-59F7A795F11C

P356

P1433

Pediatric Blood & Cancer

P1476

Initial testing (stage 1) of t ...... ic preclinical testing program

@en

P2093

Catherine Billups

http://www.w3.org/2001/XMLSchema#string

Christopher L Morton

http://www.w3.org/2001/XMLSchema#string

Doris Phelps

http://www.w3.org/2001/XMLSchema#string

E Anders Kolb

http://www.w3.org/2001/XMLSchema#string

Hernan Carol

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

Stephen T Keir

http://www.w3.org/2001/XMLSchema#string

P2860

TOR signaling in growth and metabolism

The role of integrin-linked kinase (ILK) in cancer progression

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

The TOR pathway: a target for cancer therapy

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

P304

191-199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.22935

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Richard G Gorlick

Malcolm A Smith

P577

2011-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21337679

http://www.w3.org/2001/XMLSchema#string

P932

4304209

http://www.w3.org/2001/XMLSchema#string